Filtered By:
Procedure: Anoscopy
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
CONCLUSIONS: This trial showed significantly higher anti-HR-HPV antibody titres in vaccinated individuals than in unvaccinated controls. There were no serious adverse events attributable to the vaccine. In our cohort, 1 of every 7 patients had HSIL and the prevalence of combined infection by genotypes 16 and 18 was low. This suggests that patients could benefit from receiving qHPV vaccine. Older age was the main protective factor against HR-HPV infection, and non-suppressed HIV viremia was a risk factor. Clinical trial registration: ISRCTN14732216 (http://www.isrctn.com/ISRCTN14732216).
PMID: 28729879 [PubMed - in process]
Source: AIDS Research and Therapy - July 23, 2017 Category: Infectious Diseases Authors: Hidalgo-Tenorio C, RamÃrez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, Lopez-Ruz M, Pasquau J Tags: AIDS Res Ther Source Type: research
